Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Tumor Lysis Syndrome 2Lymphoma 1Leukemia 1Inflammation 1Hyperuricemia 1Hematologic Neoplasms 1Gout 1Cardiovascular Diseases 1Arthritis 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Febuxostat × Clear all
NCT03605212 2021-06-03

FLORET

Menarini Group

Phase 1/2 Terminated
30 enrolled 14 charts
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

NCT02500641 2019-06-21

FORWARD

Menarini International Operations Luxembourg SA

Phase 4 Completed
196 enrolled 9 charts

Arthritis, Cardiovascular Diseases, Gout, Inflammation, Hyperuricemia

NCT01724528 2014-11-03

FLORENCE

Menarini Group

Phase 3 Completed
346 enrolled 16 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡